ArticleOrphanet journal of rare diseases2026
The role of neuroimmunology subspecialty in disease management of patients with neuromyelitis optica spectrum disorder.
Article in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeuromyelitis optica spectrum disorder (NMOSD) is a severe autoimmune inflammatory disease of the central nervous system (CNS) that requires specialized management. Although the role of subspecialty management has been established in various neurological conditions, the impact of neuroimmunology subspecialty (NIS) management on NMOSD patient outcomes remains inadequately explored.
methodsA retrospective analysis was conducted on 188 NMOSD patients, stratifying them into groups based on their management pathway: initial visit in NIS, initial visit in non-neuroimmunology subspecialty (NNIS), NNIS-to-NIS transfer, and last visit in either NIS or NNIS. Primary outcome measures included annualized relapse rate (ARR), Expanded Disability Status Scale (EDSS) scores.
resultsPatients initially presenting to NIS IV demonstrated a lower ARR (median: 0.39, IQR: 0.31-0.51, 95% confidence interval (CI): 0.33-0.45) compared to other groups at last follow-up. For transfer patients, ARR significantly decreased post-transfer (p < 0.001). Patients in NIS IV group had the lowest EDSS scores (median: 1.3, IQR: 1.0-2.0, 95% CI: 1.0-2.0) compared to other groups. Both initial presentation to NIS (OR:0.50, 95%CI:0.26-0.97, p = 0.039) and subsequent transfer to NIS management (OR:0.41, 95%CI:0.21-0.81, p = 0.010) were associated with lower EDSS scores.
conclusionNIS management significantly improves outcomes in NMOSD patients, as evidenced by lower relapse rates, reduced disability scores, and higher utilization of advanced therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.